The siXkr8/Dox@PMLC nanoplatform creates a self-amplifying drug delivery cascade where doxorubicin-triggered apoptotic bodies become secondary drug carriers, penetrating deep hypoxic tumor regions where cancer stem cells reside. The system silences Xkr8 scramblase to prevent phosphatidylserine exposure, allowing drug-loaded apoptotic bodies to evade M2 macrophage clearance while simultaneously blocking the CD24/Siglec-10 immune checkpoint axis. This biomimetic approach represents a sophisticated departure from conventional nanomedicine by transforming cellular death into a propagating therapeutic mechanism. The strategy addresses two critical cancer therapy challenges: reaching inaccessible stem cell niches and overcoming immune suppression. While promising for targeting treatment-resistant cancer populations, the complexity of this multi-component system raises questions about manufacturing scalability and potential off-target effects. The reliance on apoptotic body generation also assumes sufficient initial drug uptake to trigger the cascade. This proof-of-concept work opens possibilities for similar cascade-amplified therapies, though extensive safety validation will be essential given the novel mechanism of hijacking natural cellular death processes for therapeutic advantage.